<?xml version="1.0" encoding="UTF-8"?>
<p>When analyzing the Ig profiles of the 26 patients, we observed that 18 (69.2%) of them developed both anti-EBOV IgM and IgG (survivors = 12, fatal = 6) and 5 (19.2%) presented IgG (4 patients, survivors = 1, fatal = 3) or IgM (1 fatal patient) only; 3 (11.5%) patients, all fatal, did not develop specific IgM nor IgG within the timeframe considered in the study.</p>
